Supplemental Table 4. Multivariable linear regression analysis of associations of change in PON1 with change in DAS28-CRP, and CDAI after 6 months of biologic therapy, controlling for percent change in HDL.

	Total Cohort	TNFi	RTX	ABA	TCZ
Change in DAS28-CRP- Adjusted Model ($\triangle$%HDL)					
PON#	-0.83 (0.35)*	-1.18 (0.62)	-1.37 (1.22)	-0.99 (0.64)	-0.14 (0.64)
LAC#	-0.66 (0.27)*	-0.52 (0.42)	0.70 (0.97)	-1.28 (0.49)*	-0.63 (0.56)
ARYL#	-0.79 (0.28)*	-0.87 (0.47)	-0.67 (0.95)	-0.96 (0.47)*	-0.50 (0.65)
Change in CDAI- Adjusted Model ($\triangle$%HDL)					
PON#	-6.22 (3.57)	-11.00 (6.56)	-10.04 (12.53)	-8.74 (6.46)	1.44 (6.43)
LAC#	-4.91 (2.76)	-3.67 (4.45)	3.14 (9.99)	-13.61 (4.98)*	0.64 (5.81)
ARYL#	-6.02 (2.93)*	-5.67 (4.94)	-9.81 (9.71)	-9.53 (4.80)*	-0.26 (6.71)

Values are model coefficient estimate (SE).

General linear models with differences of DAS28-CRP and CDAI from 0 to 6 months as the dependent variable, controlling for seropositivity, RA disease duration, BMI, and percent change in HDL from baseline to 6 months.

PON1 values are difference in $\log_{10}X$ from 0 to 6 months. Units are Log(U/mL).

*$p<0.05$

PON=paraoxonase; LAC=lactonase; ARYL=arylesterase; BMI=body mass index (kg/m^2); seropositive=+RF or CCP; TNFi=tumor necrosis factor inhibitor; RTX=rituximab; ABA=abatacept; TCZ=tocilizumab.